Tpl2 kinase inhibitors are primarily used in research and therapeutic applications targeting inflammatory diseases and cancer. They work by blocking the Tpl2 kinase enzyme, which plays a key role in signaling pathways that drive inflammation and cell proliferation. In inflammatory conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, these inhibitors help reduce the production of pro-inflammatory cytokines, alleviating symptoms and slowing disease progression. In cancer research, Tpl2 kinase inhibitors are studied for their potential to suppress tumor growth by disrupting signaling pathways that promote cancer cell survival and proliferation. Their ability to modulate immune responses also makes them a candidate for combination therapies with other anticancer or anti-inflammatory drugs. Ongoing studies aim to optimize their efficacy and safety for clinical use.